Magnus Rasmussen
21 – 30 of 153
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population–first results from a cohort study in Southern Sweden
(
- Contribution to journal › Article
-
Mark
Blood culture time to positivity in non-β-hemolytic streptococcal bacteremia as a predictor of infective endocarditis-a retrospective cohort study
(
- Contribution to journal › Article
-
Mark
Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases
(
- Contribution to journal › Article
-
Mark
Surveillance of COVID-19 vaccine effectiveness : A real-time case-control study in southern Sweden
(
- Contribution to journal › Article
-
Mark
Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022
2022) In Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 27(9).(
- Contribution to journal › Article
-
Mark
Treatment Strategies and Risk of Recurrence in Patients with Heart Valve Prosthesis, Staphylococcus aureus Bacteremia, and Possible Endocarditis - A Retrospective Cohort Study
(
- Contribution to journal › Article
-
Mark
Bacteraemia and infective endocarditis with Streptococcus bovis-Streptococcus equinus-complex: a retrospective cohort study
(
- Contribution to journal › Article
-
Mark
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
(
- Contribution to journal › Article
-
Mark
True infection or contamination in patients with positive Cutibacterium blood cultures-a retrospective cohort study
(
- Contribution to journal › Article
-
Mark
COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants: surveillance results from southern Sweden, December 2021 to March 2022
2022)(
- Working paper/Preprint › Preprint in preprint archive